Overview

Cancer cells, including glioblastoma (GBM) tumor cells that are highly resistant to all known therapies, express tumor-specific receptors, IL-13RA2 and EphA2 (these receptors are not present in normal cells). The breakthrough of WPD Pharmaceuticals’ solution will be based on the use of therapy targeting IL-13RA2 and EphA2 receptors by recombinant proteins IL-13 and Ephrin 1 proteins, conjugated to Pseudomonas and Diphtheria bacteria toxins.

WP1066 represents a new class of drugs, which WPD calls “Immune/Transcription Modulators”. WP1066 and related analogs have not only demonstrated the ability to directly induce apoptosis (tumor cell death) but also the ability to stimulate an immune response to tumors allowing T-cells to attack tumor cells. Based on preclinical testing, WP1732 is a potential breakthrough discovery, a new fully water-soluble p-STAT3 inhibitor technology complementary to orally bioavailable non-water-soluble WP1066. STAT3 inhibitors are an essential part of our efforts to develop new cancer treatments that effectively target highly resistant tumors.

Uveal melanoma (UV), a rare but deadly cancer of the eye that often rapidly progresses to the liver is characterized by the expression of the tumor-specific receptors IL-13RA2, which are not detected in normal cells, and which express mainly IL-13RA1. The breakthrough of WPD Pharmaceuticals’ solution will be based on the use of targeted therapy against IL-13RA2 by genetically modified IL-13 conjugated to a cytotoxic load ("Warhead").

WPD103 is a radiopharmaceutical based on the expression of tumor-specific receptors, such as IL-13RA2 and EphA2, which are not detected in normal cells, which express mainly IL-13RA1 and Eph-RA1 proteins. The breakthrough of WPD Pharmaceuticals’ solution is expected to be a new diagnostic tool and targeted therapy against IL-13RA2 and EphA2 receptors by genetically modified IL-13 and Ephrin 1 cytokines, conjugated to radionuclides.